×
About 1,033 results

ALLMedicine™ Xeroderma Pigmentosum Center

Research & Reviews  394 results

Management of coexisting bilateral ocular surface disease in xeroderma pigmentosum - se...
https://doi.org/10.1177/11206721221100903
European Journal of Ophthalmology; Rajagopal R, Srinivasan B et. al.

May 11th, 2022 - To report a rare presentation of bilateral, coexisting ocular surface disease in a case of Xeroderma pigmentosum and its successful management. Case report. A 21-year-old male with Xeroderma pigmentosum presented with bilateral ocular surface squa...

XPA Enhances Temozolomide Resistance of Glioblastoma Cells by Promoting Nucleotide Exci...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096195
Cell Transplantation; Dai W, Wu A et. al.

May 11th, 2022 - Glioblastoma is the most frequent, as well as aggressive kind of high-grade malignant glioma. Chemoresistance is posing a significant clinical barrier to the efficacy of temozolomide-based glioblastoma treatment. By suppressing xeroderma pigmentos...

Poikiloderma with neutropenia: An alternate presentation with dyspigmentation and novel...
https://doi.org/10.1111/pde.15007
Pediatric Dermatology; Peterson MY, Hanson B et. al.

May 7th, 2022 - Two siblings presented with sun sensitivity and progressive dyspigmentation. A diagnosis of xeroderma pigmentosum was initially favored due to XPC mutations, although variants were not clearly diagnostic. However, new moderate neutropenia and homo...

Identifying the psychosocial predictors of ultraviolet exposure to the face in patients...
https://doi.org/10.1136/jmedgenet-2021-108323
Journal of Medical Genetics; Sarkany R, Norton S et. al.

Apr 9th, 2022 - For patients with xeroderma pigmentosum (XP), the main means of preventing skin and eye cancers is extreme protection against ultraviolet radiation (UVR), particularly for the face. We have recently developed a methodology for objectively measurin...

Xeroderma Pigmentosum - GeneReviews® - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/n/gene/xp/

Mar 24th, 2022 - Xeroderma pigmentosum (XP) is characterized by:

see more →

Drugs  1 results see all →

Clinicaltrials.gov  6 results

XPAND Trial: Enhancing XP Photoprotection Activities - New Directions
https://clinicaltrials.gov/ct2/show/NCT03445052

Jul 22nd, 2020 - Xeroderma Pigmentosum (XP) is a rare autosomal recessive inherited condition caused by defective Nucleotide Excision Repair. Patients may develop skin cancers from childhood onwards, ocular damage, and neurological deterioration. The clinical mana...

T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum
https://clinicaltrials.gov/ct2/show/NCT00002811

Nov 6th, 2013 - OBJECTIVES: I. Compare the safety and efficacy of T4N5 liposome lotion vs. a placebo lotion in reducing the incidence of actinic keratoses and protecting against other ultraviolet skin damage in patients with xeroderma pigmentosum. OUTLINE: Random...

S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
https://clinicaltrials.gov/ct2/show/NCT00086996

Oct 11th, 2013 - OBJECTIVES: Primary Determine the pathologic complete response probability in patients with stage II or III adenocarcinoma of the esophagus or gastroesophageal junction treated with neoadjuvant oxaliplatin, fluorouracil, and radiotherapy followed ...

Isotretinoin in Preventing Skin Cancer
https://clinicaltrials.gov/ct2/show/NCT00025012

Jun 19th, 2013 - OBJECTIVES: I. Determine the lowest effective dose of oral isotretinoin for long-term therapy that is capable of reducing the rate of formation of new skin cancers in patients with xeroderma pigmentosum or nevoid basal cell carcinoma syndrome. II....

DNA Repair Genes and Outcomes in Patients With Stage III NSCLC
https://clinicaltrials.gov/ct2/show/NCT00797238

Jul 15th, 2010 - Patients with clinical stage IIIA N2 non-small cell lung cancer (NSCLC) have a 5-year survival rate of 10% to 15%, much worse than those of earlier stages of disease. The use of pre-operative (neo-adjuvant) chemotherapy has been shown to be benefi...

see more →

News  11 results

Fast Five Quiz: Malignant Melanoma
https://reference.medscape.com/viewarticle/936083_2

Aug 21st, 2020 - Primary risk factors and clinical warning signs for melanoma include: Changing mole (most important clinical warning sign) Presence of xeroderma pigmentosum or familial atypical mole melanoma syndrome Clinical atypical/dysplastic nevi in familial ...

NHS England Boss Knighted in New Year Honours
https://www.medscape.com/viewarticle/923186

Dec 28th, 2019 - Simon Stevens, head of NHS England becomes a Sir, leading this year's healthcare field in the 2020 New Year Honours List. The recipients in healthcare are alongside stars of sport, entertainment, public service, politics, charity work, and "the ou...

Expert spotlights telltale clinical signs of xeroderma pigmentosum
https://www.mdedge.com/pediatrics/article/207921/pediatrics/expert-spotlights-telltale-clinical-signs-xeroderma-pigmentosum?channel=39313
Doug Brunk

Sep 10th, 2019 - AUSTIN, TEX. – If a child presents with acute photosensitivity at a young age, onset of freckling before the age of 2 years, and severe sun damage of the lips and eyes, think xeroderma pigmentosum (XP), a rare autosomal recessive disorder.

Small Kansas Town Turns Night Into Day for Boy With Rare Disease
https://www.mdedge.com/clinicianreviews/article/150902/rare-diseases/small-kansas-town-turns-night-day-boy-rare-disease

Nov 1st, 2017 - A new documentary video developed by NORD shows how a small community in Kansas came together to support an 11-year-old boy who has a rare disease that makes it necessary for him to avoid sunlight. Peyton Madden has xeroderma pigmentosum (XP), a r.

Solitary Nodular Lesion on the Scalp
https://www.mdedge.com/dermatology/article/80780/nonmelanoma-skin-cancer/solitary-nodular-lesion-scalp
Sotonye Imadojemu, MD, Mbe, Douglas J. Pugliese, MD, MPH et. al.

Mar 4th, 2014 - The Diagnosis: Pilomatricoma Pilomatricoma, first described by Malherbe and Chenantais1 in 1880, is a benign appendageal tumor derived from hair follicle matrix cells. It classically manifests as a solitary, asymptomatic, firm dermal nodule with a.

see more →

Patient Education  1 results see all →